Wells Fargo analyst Stephen Baxter lowered the firm’s price target on Humana (HUM) to $290 from $347 and keeps an Overweight rating on the shares. The firm is also lowering estimates on refined star rating headwind given clarity on VBC / Group MA dynamics.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUM:
- Trump says ‘enrichment’ of health insurers ‘must stop’
- Humana price target lowered to $310 from $345 at Mizuho
- Humana price target lowered to $231 from $250 at Deutsche Bank
- Humana’s Hold Rating: Balancing Positive Earnings with Strategic Challenges
- Humana’s Strategic Focus on Medicare Advantage and Future Margin Expansion Amidst Uncertain Guidance